Cambridge Investment Research Advisors
ACHN

Cambridge Investment Research Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-21,880
Closed -$98K – 2188
2017
Q3 		$98K Sell
21,880
-1,250
-5% -$5.55K ﹤0.01% 1924
2017
Q2 		$106K Buy
23,130
+800
+4% +$3.22K ﹤0.01% 1846
2017
Q1 		$94K Buy
22,330
+200
+0.9% +$830 ﹤0.01% 1704
2016
Q4 		$91K Sell
22,130
-8,305
-27% -$44.1K ﹤0.01% 1596
2016
Q3 		$247K Sell
30,435
-2,075
-6% -$17.6K ﹤0.01% 1420
2016
Q2 		$254K Sell
32,510
-125
-0.4% -$1.07K 0.01% 1254
2016
Q1 		$252K Sell
32,635
-9,145
-22% -$67K 0.01% 1268
2015
Q4 		$451K Buy
41,780
+19,975
+92% +$182K 0.01% 895
2015
Q3 		$151K Buy
21,805
+9,150
+72% +$74.5K ﹤0.01% 1312
2015
Q2 		$112K Buy
12,655
+100
+0.8% +$946 ﹤0.01% 1364
2015
Q1 		$124K Buy
+12,555
New +$157K ﹤0.01% 1325

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Cambridge Investment Research Advisors's ACHN Position: Q4 2017 in Review

Cambridge Investment Research Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q4 2017, closing a stake of 21,880 shares — an estimated $98K sold.

Cambridge Investment Research Advisors first reported a position in ACHN in Q1 2015 and held it in 11 quarters. The position peaked at $451K in Q4 2015. 149 funds tracked by Wall St. Rank hold ACHN as of Q4 2017.

  • Cambridge Investment Research Advisors reported no remaining Achillion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 21,880 Achillion Pharmaceuticals shares in Q4 2017, an estimated $98K.
  • Cambridge Investment Research Advisors first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • Cambridge Investment Research Advisors's Achillion Pharmaceuticals position peaked at $451K in Q4 2015.
  • 149 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2017.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2017, filed 22 Feb 2018.